AI-driven cardiac risk prediction and prevention platform for health benefits
Hello Heart builds a heart-health AI platform sold through health plans and employers, running a mobile stack (React Native, TypeScript) over Scala/Play, Go and Java services with a Spark, Kafka, Snowflake, dbt and Airflow data layer. Hiring is accelerating and skews senior and executive, led by sales, with legal roles tied to an AI governance program, privacy work and future FDA-regulated capabilities. That points to a push into regulated clinical territory alongside channel expansion.
Hello Heart is a privately held digital health company founded in 2013 and headquartered in Menlo Park, California, with 201–500 employees. It develops an AI platform focused solely on heart health, aimed at spotting near-term cardiac risk and helping prevent events such as heart attacks. The company sells to large U.S. health plans and to public and private employers as a preventive health benefit. It hires in the United States and Israel across sales, engineering, product, support, legal and data functions.
Hello Heart uses React Native, React and TypeScript on the front end, Scala/Play, Java, Go and Node.js services on AWS with Docker and Kubernetes, and Spark, Kafka, Snowflake, dbt and Airflow for data.
Hello Heart is headquartered in Menlo Park, California, and hires in both the United States and Israel.
Current initiatives include an AI governance program, expansion into the Taft-Hartley labor union market, Medicare partnership development, a privacy program and groundwork for future FDA-regulated capabilities.
Other companies in the same industry, closest in size
Hello Heart's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.